Evidence map›Paper›PMID 28551845›Full record

ArticleMolecular and cellular biochemistry2017

SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.

Qinyi Zhou, Jun Chen, Jialin Feng, Yanan Xu, Wenjie Zheng, Jiadong Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Impact of microRNAZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Qinyi ZhouDepartment of Head and Neck Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, #145 Shandongzhong Road, Huangpu District, Shanghai, 200001, China.
Jun ChenDepartment of Head and Neck Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, #145 Shandongzhong Road, Huangpu District, Shanghai, 200001, China.
Jialin FengDepartment of Head and Neck Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, #145 Shandongzhong Road, Huangpu District, Shanghai, 200001, China.
Yanan XuDepartment of Head and Neck Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, #145 Shandongzhong Road, Huangpu District, Shanghai, 200001, China.
Wenjie ZhengDepartment of Head and Neck Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, #145 Shandongzhong Road, Huangpu District, Shanghai, 200001, China.
Jiadong WangDepartment of Head and Neck Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, #145 Shandongzhong Road, Huangpu District, Shanghai, 200001, China. wangjiadong097@gmail.com.ORCID http://orcid.org/0000-0001-5296-7537
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sclerostin domain containing protein 1 (SOSTDC1) is a cell signaling regulator involved in cell physiology and pathology. SOSTDC1 is known to have a suppressive effect on certain kinds of cancer. However, the role of SOSTDC1 in follicular thyroid cancer (FTC) remains unknown. We aimed to investigate if the expression of SOSTDC1 plays any roles in carcinogenesis and metastasis of FTC. We found a significantly down-regulated SOSTDC1 expression in follicular thyroid cancer samples. In addition, our data showed that ectopic expression of SOSTDC1 dramatically inhibited thyroid cancer cell proliferation in vitro and in nude mice. SOSTDC1 also compromised the migratory, invasive property, and epithelial-mesenchymal transition (EMT) activity of FTC cell. Mechanically, SOSTDC1 exerted its tumor suppressor function by inhibiting the activity of major signaling pathways including the phosphatidylinositol-3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/Erk pathways. Altogether, our findings provide insight into the role of SOSTDC1 as a novel functional tumor suppressor in follicular thyroid cancer through modulating the activities of PI3K/Akt and MAPK/Erk signaling pathways.

Indexed as

Cell MovementCell ProliferationEpithelial-Mesenchymal TransitionMAP Kinase Signaling SystemAdaptor Proteins, Signal TransducingAdenocarcinoma, FollicularCell Line, TumorFemaleHumansIntracellular Signaling Peptides and ProteinsMalePhosphatidylinositol 3-KinasesProteinsProto-Oncogene Proteins c-aktThyroid NeoplasmsTumor Suppressor ProteinsAdaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-KinasesProteinsProto-Oncogene Proteins c-aktSOSTDC1 protein, humanTumor Suppressor ProteinsCell proliferationFollicular thyroid cancerMAPK/ErkMigrationPI3K/AktSOSTDC1

Identifiers

PMID28551845
OpenAlexW2618999013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.